Skip to content
Peptide research

PE-22-28

Also known as Spadin Analog · Mini-Spadin
Category
Brain & Cognition
Regulatory status
Not FDA-approved

A spadin-derived peptide marketed for rapid antidepressant effects by blocking brain TREK-1 channels, giving a ketamine-like mood lift via a different pathway. Evidence is preclinical, from rodent studies, with no human trials and speculative cognitive claims. The headline gap is safety: no human safety data exists, and cell-proliferation and SSRI/SNRI concerns are unresolved. It has no approved use and is sold only as an unregulated research chemical.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

PE-22-28 (Mini-Spadin) is a synthetic seven-amino-acid peptide being researched as a rapid-acting antidepressant. It was developed at France's CNRS/IPMC institute by optimizing Spadin, a naturally occurring antidepressant peptide discovered in 2010. PE-22-28 works by blocking the TREK-1 potassium channel in the brain -- a channel that normally dampens nerve cell activity. By inhibiting TREK-1, it increases serotonin signaling, boosts BDNF (the brain's key growth factor), and stimulates the growth of new brain cells in the hippocampus, the brain's memory and mood center.

How it works in the body

A small peptide derived from the spadin family that acts as an antagonist of TREK-1 potassium channels in the brain. When TREK-1 channels are blocked, neurons become more excitable and serotonin signaling increases. This produces rapid antidepressant-like effects, similar in mechanism to ketamine but through a different target.

Research overview

PE-22-28 is approximately 400 times more potent than its parent compound Spadin at blocking TREK-1 channels (IC50 of 0.12 nM). In mouse studies, it produces antidepressant effects within just 4 days -- compared to 3-4 weeks for SSRIs like fluoxetine (Prozac). It roughly doubles the rate of new brain cell growth in the hippocampus and enhances formation of synaptic connections. It shows no activity on heart potassium channels (hERG), suggesting a favorable cardiac safety profile. However, all research is from a single French lab (about 20 publications total on Spadin/TREK-1), no human trials have been conducted, and no clinical development timeline has been publicly disclosed.

Who researches PE-22-28?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching rapid-onset antidepressant activity

    One of the primary studied benefits of PE-22-28.

Important considerations for

  • Those with Concurrent serotonergic medications (SSRIs, SNRIs, MAOIs)

    High

    TREK-1 channel blockade has antidepressant effects. Combined with serotonergic drugs, risk of excessive monoamine activity.

  • Those with Cardiac arrhythmias

    Moderate

    TREK-1 channels are expressed in cardiac tissue. Preclinical data shows no cardiac effects but human data lacking.

  • Those who are pregnant or breastfeeding

    Absolute

    No human data. Entirely preclinical — TREK-1 channels play roles in neurodevelopment.

Safety & interactions

Do not use if

  • Concurrent serotonergic medications (SSRIs, SNRIs, MAOIs)

    High

    TREK-1 channel blockade has antidepressant effects. Combined with serotonergic drugs, risk of excessive monoamine activity.

  • Cardiac arrhythmias

    Moderate

    TREK-1 channels are expressed in cardiac tissue. Preclinical data shows no cardiac effects but human data lacking.

General cautions

  • Pregnancy

    Absolute

    No human data. Entirely preclinical — TREK-1 channels play roles in neurodevelopment.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(5)

Rated by level of concern

  • No established human safety profile

    High

    Djillani A et al. 2019, Pharmacol Ther, PMID 30291907

  • Theoretical serotonin syndrome risk with SSRIs/SNRIs

    Theoretical

    Mazella J et al. 2010, PMID 20405001; Ye D et al. 2015, PMID 26441141; Djillani et al. 2019, PMID 30291907

  • Potential for uncontrolled neurogenesis or cellular proliferation

    Theoretical

    Djillani A et al. 2017, PMID 28955242; Mazella J et al. 2010, PMID 20405001

  • TREK-1 inhibition and neuroprotection trade-off

    Low

    Heurteaux C et al. 2004, EMBO J, PMID 15175651

  • Quality and purity concerns: unregulated products sold online vary in purity

    High

    No FDA-regulated source identified

Interaction summary(5)

Rated by direction with this peptide

  • SSRIs/SNRIs (fluoxetine, paroxetine, citalopram, sertraline, venlafaxine)

    CautionTheoretical

    Converging serotonergic/TREK-1 mechanism raises a theoretical additive effect; no human co-administration data or adverse events reported.

    Mazella J et al. 2010, PMID 20405001; Ye D et al. 2015, PMID 26441141; Djillani A et al. 2019, PMID 30291907

  • 5-HT1A receptor agonists/partial agonists (e.g., buspirone)

    SynergisticTheoretical

    Preclinical synergy via shared CREB pathway signaling in rat chronic-stress models; no human data.

    Ye D et al. 2015, Eur Neuropsychopharmacol, PMID 26441141

  • MAOIs (phenelzine, tranylcypromine)

    CautionTheoretical

    Never directly tested; theoretical caution from serotonergic-adjacent mechanism combined with MAOI-driven serotonin accumulation.

    Mechanism-based inference from Mazella J et al. 2010, PMID 20405001

  • hERG-active / QT-prolonging drugs (certain antiarrhythmics, antipsychotics)

    NeutralLow

    In vitro assays show no hERG activity for spadin/PE-22-28, arguing against direct cardiac-conduction interaction, though untested in vivo alongside such drugs.

    Djillani A et al. 2017, Front Pharmacol, PMID 28955242

  • Volatile general anesthetics (halothane, sevoflurane, isoflurane)

    CautionTheoretical

    TREK-1 underlies anesthetic neuroprotective mechanisms; antagonizing it theoretically could blunt that protection during surgery, though untested in combination.

    Heurteaux C et al. 2004, EMBO J, PMID 15175651

Known risks(5)

  • No established human safety profile

    High (Unknown)

    PE-22-28 has never been tested in humans. All safety data comes from mouse studies and cell-based assays. While animal data shows a favorable safety profile (no cardiac, pain, epilepsy, or ischemia effects), the translation of animal safety to humans is never guaranteed. Unknown human pharmacokinetics, metabolism, bioavailability, and potential toxicities represent the primary risk.

  • Theoretical serotonin syndrome risk with SSRIs/SNRIs

    Moderate / Theoretical

    PE-22-28 enhances serotonergic neurotransmission via TREK-1 blockade. Combining with SSRIs (fluoxetine, sertraline, citalopram), SNRIs, MAOIs, or other serotonergic agents could theoretically produce excessive serotonin system activation. While no cases of serotonin syndrome have been reported in animal models, the theoretical risk exists when combining multiple agents that act on overlapping serotonergic pathways.

  • Potential for uncontrolled neurogenesis or cellular proliferation

    Theoretical / Unknown

    PE-22-28 promotes hippocampal neurogenesis and upregulates BDNF, which activates cellular growth and survival pathways (MAPK, PI3K). Individuals with active cancer, a history of cancer, or predisposition to neoplastic conditions should exercise extreme caution, as stimulating growth pathways could theoretically promote tumor growth. No tumors have been observed in the limited animal studies conducted, but this risk has not been evaluated in long-term studies or in humans.

  • TREK-1 inhibition and neuroprotection trade-off

    Moderate / Theoretical

    TREK-1 channels play a physiological role in neuroprotection against ischemia and epilepsy: TREK-1 knockout mice show increased sensitivity to ischemia and seizures (Heurteaux et al. 2004, EMBO Journal). While spadin was shown not to interfere with these protective functions in a 2012 safety study, this was demonstrated only in acute/subchronic mouse models. The long-term consequences of sustained TREK-1 inhibition in humans, particularly in individuals at risk for stroke or seizure, remain unknown.

  • Research chemical quality and purity concerns

    Moderate

    Unregulated PE-22-28 products sold online lack pharmaceutical-grade quality controls. Purity, sterility, endotoxin levels, and actual peptide content may vary among unregulated products sold online. Contamination or degradation products could pose additional unknown risks.

Drug interactions(6)

  • SSRIs (fluoxetine, sertraline, citalopram, escitalopram, paroxetine)

    PE-22-28 enhances serotonergic neurotransmission via TREK-1 channel blockade, the same neurotransmitter system targeted by SSRIs. Combining PE-22-28 with SSRIs could theoretically produce excessive serotonin signaling, with a theoretical risk of serotonin syndrome. No cases have been reported in animal models, but the combination is entirely unstudied in humans.

  • SNRIs and MAOIs (venlafaxine, duloxetine, phenelzine, tranylcypromine)

    Both SNRIs and MAOIs increase serotonin availability through different mechanisms. Combined with PE-22-28's serotonergic enhancement via TREK-1 blockade, the theoretical risk of excessive serotonergic stimulation is amplified compared to SSRIs. MAOIs carry the highest theoretical risk due to their broad monoamine preservation.

  • Other TREK-1 modulators or potassium channel drugs

    Combining PE-22-28 with other agents that modulate TREK-1 or related K2P channels could produce unpredictable effects on neuronal excitability. Volatile anesthetics (isoflurane, halothane) are known TREK-1 activators — PE-22-28 could theoretically reduce their efficacy. Disclose PE-22-28 use before any anesthetic procedure.

  • Anti-seizure / anti-epileptic medications (carbamazepine, valproate, lamotrigine)

    TREK-1 channels play a role in neuroprotection against seizures. While spadin was shown not to increase seizure susceptibility in acute mouse models (Moha ou Maati et al. 2012), chronic TREK-1 inhibition could theoretically lower seizure threshold, potentially counteracting anti-epileptic medications. Individuals with epilepsy or seizure disorders should exercise extreme caution.

  • Other neurogenic/nootropic peptides (Semax, Selank, Dihexa, P021, NSI-189)

    Combined neurogenic stimulation from multiple compounds (PE-22-28 via TREK-1/BDNF pathway, Dihexa via HGF/c-Met, P021 via CNTF/BDNF) could produce unpredictable effects on brain plasticity and neurogenesis. While no overlapping direct targets suggest pharmacological conflict, combined neurogenic stimulation is entirely unstudied and should be approached with caution.

  • Stimulants and sympathomimetics (amphetamine, methylphenidate, caffeine)

    PE-22-28 increases neuronal excitability via TREK-1 blockade. Combining with stimulants that independently increase neuronal activity could produce excessive CNS stimulation. No interaction data exists, but the combination could theoretically produce overstimulation, anxiety, or insomnia.

Research & benefits

Evidence base

Evidence Level
Preclinical Only
Total Studies
8
Human Studies
0

All evidence for PE-22-28 comes from in vitro cell-based assays (patch-clamp electrophysiology on hTREK-1/HEK cells, cortical neuron cultures) and in vivo mouse behavioral models (forced swimming test, tail suspension test, novelty suppressed feeding test). No human clinical trials (Phase 1, 2, or 3) have been published or registered on ClinicalTrials.gov as of March 2026. The broader spadin research program (from which PE-22-28 derives) spans approximately 20 PubMed-indexed publications from 2006-2020 across multiple independent research groups at CNRS/IPMC. The preclinical evidence is consistent: PE-22-28 and spadin show robust TREK-1 inhibition, rapid antidepressant effects, neurogenesis promotion, synaptogenesis enhancement, and BDNF upregulation without cardiac or other systemic side effects. However, the absence of any human data means efficacy, pharmacokinetics, and safety in humans remain entirely unestablished. French patent FR3057266A1 covers PE-22-28 and analogs for depression treatment, indicating commercial development intent.

Researched for(6)

Rated by confidence in the evidence

  • Rapid-onset antidepressant activity

    Medium

    Consistent rodent antidepressant-like effects with a clear mechanism, but no human trials yet.

    Djillani A et al. 2017, Front Pharmacol, PMID 28955242; Mazella J et al. 2010, PLoS Biol, PMID 20405001

  • Enhanced hippocampal neurogenesis

    Medium

    Two independent rodent studies show increased neurogenesis markers, not yet tested in humans.

    Djillani A et al. 2017, PMID 28955242; Mazella J et al. 2010, PMID 20405001

  • Increased synaptogenesis and synaptic plasticity

    Medium

    Rodent and cell studies show increased synaptic protein markers, with no human data yet.

    Djillani A et al. 2017, PMID 28955242; Devader C et al. 2015, Br J Pharmacol, PMID 25598009

  • Cognitive enhancement — improved learning and memory

    Speculative

    No direct memory testing exists, and other TREK-1 research reports conflicting cognitive effects.

    Mechanism-inference; contrast data from TREK-1-null Mol Neurobiol study and Wu et al. 2022, PMID 35678977

  • Favorable cardiac and neurological safety profile

    Low

    Animal and cell studies suggest channel selectivity and no side effects, but zero human safety data.

    Djillani A et al. 2017, PMID 28955242; Moha Ou Maati H et al. 2012, Neuropharmacology, PMID 21807005

  • Neuroprotective potential via BDNF upregulation

    Low

    One rat study found increased BDNF signaling in several brain regions, not tested in humans.

    Ye D et al. 2015, Eur Neuropsychopharmacol, PMID 26441141 (direct spadin BDNF-pathway data, supersedes the data-gap noted in Mazella J et al. 2010, PMID 20405001)

Benefits(6)

  • Rapid-onset antidepressant activity

    Djillani et al. 2017 (PMID 28955242) — PE-22-28 produced significant antidepressant effects in the forced swimming test (reduced immobility time) and novelty suppressed feeding test (reduced latency to eat) after only 4 days of treatment at 4 microg/kg/day IP in mice. Foundational spadin work: Mazella et al. 2010 (PMID 20405001) showed spadin produced antidepressant effects in 4 days vs. several weeks for fluoxetine.

  • Enhanced hippocampal neurogenesis

    Djillani et al. 2017 (PMID 28955242) — 4-day treatment with PE-22-28 (4 microg/kg/day IP) significantly increased BrdU-positive cells in the hippocampus (1736 +/- 126) compared to saline controls (899 +/- 109), representing an approximate doubling of newly born cells. The G/A-PE 22-28 analog showed an even more prominent neurogenic effect (2110 +/- 132).

  • Increased synaptogenesis and synaptic plasticity

    Djillani et al. 2017 (PMID 28955242) — PE-22-28 enhanced synaptogenesis measured by increased PSD-95 expression levels on mouse cortical neurons. Devader et al. 2015 (PMID 25598009) — Spadin enhanced both mRNA expression and protein levels of PSD-95 and synapsin (synaptogenesis markers), increased proportion of mature dendritic spines, and activated MAPK and PI3K signaling pathways in cortical neurons.

  • Cognitive enhancement — improved learning and memory

    Djillani et al. 2017 (PMID 28955242) — PE-22-28 enhanced hippocampal BDNF and CREB phosphorylation, both critical mediators of memory consolidation and learning. Mazella et al. 2010 (PMID 20405001) — spadin increased hippocampal phosphorylation of CREB, a key marker associated with learning and long-term memory formation. The cited study did not directly test learning or memory performance.

  • Favorable cardiac and neurological safety profile

    Djillani et al. 2017 (PMID 28955242) — PE-22-28 showed no activity on hERG cardiac potassium channels and no inhibition of TREK-2, TRAAK, TRESK, or TASK-1 channels, indicating high selectivity. Moha ou Maati et al. 2012 (PMID 21807005) — spadin (parent compound) did not induce cardiac dysfunctions, did not block IKr or IKs, did not modify systolic pressure or cardiac pulse, and did not interfere with pain perception, epilepsy susceptibility, or ischemia vulnerability.

  • Neuroprotective potential via BDNF upregulation

    Devader et al. 2015 (PMID 25598009) — in vivo spadin injections led to rapid increases in both mRNA expression and protein levels of BDNF in the hippocampus. BDNF is a key mediator of neuronal survival, synaptic maintenance, and protection against neurodegenerative processes. PE-22-28's 400-fold greater potency at TREK-1 suggests at least equivalent BDNF upregulation.

Key studies(7)

  1. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype

    Preclinical (in vivo, TREK-1 knockout mice)Multiple cohorts of TREK-1 -/- and wild-type miceAcute behavioral testing across five depression models

    Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thummler S, Peng XD, Noble F, Blondeau N, Widmann C, Borsotto M, Gobbi G, Vaugeois JM, Debonnel G, Lazdunski M

    Nature Neuroscience

    2006

    Foundational study establishing TREK-1 as a depression target. Deletion of the TREK-1 gene (Kcnk2) in mice produced a depression-resistant phenotype across five behavioral models: forced swim test, tail suspension test, conditioned suppression of motility, learned helplessness, and novelty suppressed feeding. TREK-1 knockout mice showed increased efficacy of 5-HT neurotransmission and substantially reduced corticosterone elevation under stress, behaving similarly to naive animals treated with fluoxetine.

  2. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design

    Preclinical (in vitro + in vivo, mice)Multiple cohorts of C57BL/6J mice4-day IV treatment

    Mazella J, Petrault O, Lucas G, Deval E, Beraud-Dufour S, Gandin C, El-Yacoubi M, Widmann C, Guyon A, Chevet E, Taouji S, Conductier G, Corinus A, Coppola T, Gobbi G, Nahon JL, Heurteaux C, Borsotto M

    PLoS Biology

    2010

    Discovery of spadin as the first natural antidepressant peptide. Spadin, a 17-amino-acid peptide derived from the sortilin propeptide, specifically blocks TREK-1 with an affinity of 10 nM. A 4-day IV spadin treatment produced strong antidepressant effects, enhanced hippocampal phosphorylation of CREB, and promoted neurogenesis — acting much faster (4 days) than fluoxetine (3-4 weeks). Spadin did not inhibit other K2P channels.

  3. Spadin as a new antidepressant: absence of TREK-1-related side effects

    Preclinical (in vitro + in vivo, safety study)Multiple cell lines and mouse cohortsAcute and subchronic treatment

    Moha ou Maati H, Veyssiere J, Labbal F, Coppola T, Gandin C, Widmann C, Mazella J, Heurteaux C, Borsotto M

    Neuropharmacology

    2012

    Dedicated safety study for spadin. Despite blocking TREK-1, spadin did not induce cardiac dysfunctions, did not block IKr or IKs currents, did not modify systolic pressure or cardiac pulses, and did not interfere with TREK-1-controlled functions including pain perception, epilepsy susceptibility, and ischemia vulnerability. Spadin was unable to inhibit currents generated by TREK-2, TRAAK, TASK, and TRESK K2P channels, confirming high selectivity.

  4. In vitro and in vivo regulation of synaptogenesis by the novel antidepressant spadin

    Preclinical (in vitro cortical neurons + in vivo mice)Primary cortical neuron cultures and mouse cohorts4-day in vivo treatment; 24-hour in vitro exposure

    Devader C, Khayachi A, Veyssiere J, Moha ou Maati H, Roulot M, Moreno S, Borsotto M, Martin S, Heurteaux C, Mazella J

    British Journal of Pharmacology

    2015

    Spadin increased neuronal membrane potential and activated both MAPK and PI3K signaling pathways in a time- and concentration-dependent manner. Enhanced mRNA and protein expression of PSD-95 and synapsin (synaptogenesis markers), significantly increased proportion of mature dendritic spines in cortical neurons, and produced rapid BDNF upregulation (mRNA and protein) in the hippocampus in vivo.

  5. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity

    Preclinical (in vitro hTREK-1/HEK cells + in vivo mice)hTREK-1/HEK293 cells; multiple cohorts of C57BL/6 mice4-day IP treatment (3.0-4.0 microg/kg/day)

    Djillani A, Pietri M, Moreno S, Heurteaux C, Mazella J, Borsotto M

    Frontiers in Pharmacology

    2017

    Key study introducing PE-22-28. The 7-amino-acid peptide PE 22-28 displayed an IC50 of 0.12 nM for TREK-1 inhibition, 400-fold more potent than spadin. PE-22-28 was specific to TREK-1 and did not affect TREK-2, TRAAK, TRESK, TASK-1, or hERG channels. In vivo, PE-22-28 produced significant antidepressant effects in the forced swimming test and novelty suppressed feeding test after 4 days. Neurogenesis was approximately doubled (BrdU-positive cells: 1736 vs. 899 for saline). Synaptogenesis was enhanced (increased PSD-95 expression).

  6. Djillani A, Mazella J, Heurteaux C, Borsotto M

    Pharmacology & Therapeutics

    2019

    Comprehensive review summarizing all TREK-1 blocker research including PE-22-28. Describes strategies used to optimize spadin: retro-inverso strategy, cyclization, and sequence shortening. Shortened spadin analogs (PE-22-28 and derivatives) present increased inhibition potency for TREK-1, improved antidepressant activity, and prolonged in vivo bioavailability. States that the final goal is to complete preclinical development before launching clinical trials in humans.

  7. Mazella J, Borsotto M

    Frontiers in Pharmacology

    2019

    Review describing the molecular biology of sortilin/NTSR3 as the progenitor of spadin, and the dual role of sortilin in both generating the antidepressant peptide spadin and regulating TREK-1 membrane expression. The antidepressant spadin was discovered from the observation that both TREK-1 and sortilin-deficient mice behaved very similarly in depressive-like behavioral tests.

Regulation & availability

Why researchers look at it

Targets the TREK-1 potassium channel — genetically validated when knockout mice proved completely depression-resistant — producing antidepressant effects within 4 days versus 3-4 weeks for SSRIs, while doubling hippocampal neurogenesis. Approximately 400x more potent than its parent compound Spadin, but all research originates from a single French lab with zero human data.

FDA status
Not FDA-approved; published evidence is preclinical. No approved human indication or publicly confirmed IND was identified. PE-22-28 does not appear on FDA's current 503A positive bulks list or interim categories. Advertised compounded preparations do not establish lawful compounding eligibility.
WADA status
Not Explicitly Listed on the 2026 WADA Prohibited List. PE-22-28 is not specifically named as a prohibited substance by the World Anti-Doping Agency. However, WADA Section S0 (Non-Approved Substances) prohibits 'any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use.' Since PE-22-28 has no regulatory approval for human use anywhere in the world, it could potentially fall under the S0 category. Athletes subject to anti-doping testing should treat PE-22-28 as potentially prohibited and consult their sport's anti-doping authority before use.
Prescribability
Not FDA-approved; a preclinical investigational compound, in development by the CNRS/IPMC research group in France. No approved human indication or established US prescription-compounding pathway was identified. A pharmacy listing of a compounded preparation or a physician prescription does not establish eligibility under section 503A or FDA approval.
Availability
PE-22-28 is not FDA-approved, and no human therapeutic authorization was identified. Listings of compounded preparations do not establish FDA approval or eligibility under sections 503A or 503B. Human efficacy, safety, and an established administration route remain unconfirmed.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(7)

  1. 2006
    Heurteaux et al. publish landmark study in Nature Neuroscience demonstrating that TREK-1 knockout mice display a depression-resistant phenotype, establishing TREK-1 as a novel antidepressant drug target
  2. 2010
    Mazella et al. publish in PLoS Biology the discovery of spadin as the first natural antidepressant peptide — a 17-amino-acid sortilin-derived peptide that blocks TREK-1 and produces rapid-onset antidepressant effects in 4 days
  3. 2012
    Moha ou Maati et al. publish dedicated safety study in Neuropharmacology confirming spadin lacks TREK-1-related side effects on cardiac function, pain, epilepsy, and ischemia vulnerability
  4. 2015
    Devader et al. publish in British Journal of Pharmacology demonstrating spadin's regulation of synaptogenesis via PSD-95 and synapsin upregulation, and BDNF induction in hippocampus
  5. 2017
    Djillani et al. publish PE-22-28 discovery in Frontiers in Pharmacology — shortened spadin analog with 400-fold improved potency (IC50 0.12 nM), longer action demonstrated for modified derivatives, antidepressant and neurogenic activity. French patent FR3057266A1 filed by CNRS covering PE-22-28 and analogs
  6. 2019
    Two review articles published: Djillani et al. in Pharmacology & Therapeutics ('Fighting against depression with TREK-1 blockers') and Mazella & Borsotto in Frontiers in Pharmacology (sortilin/NTSR3 in depression). Both state goal is to complete preclinical development before launching human clinical trials
  7. 2020-2024
    No new PE-22-28-specific publications identified. Community use expands through peptide therapy clinics and biohacking communities

Sources & FAQs

Research sources(9)

Frequently asked questions(6)

What is PE-22-28 and how does it differ from spadin?

PE-22-28 is a synthetic 7-amino-acid peptide (heptapeptide) derived from spadin, a natural 17-amino-acid peptide released from the sortilin/NTSR3 propeptide. PE-22-28 represents the shortest, most active sequence capable of blocking the TREK-1 potassium channel. Compared to spadin, PE-22-28 is approximately 400 times more potent at TREK-1 (IC50 of 0.12 nM vs. 40-60 nM) and maintains the same selectivity (no activity on TREK-2, TRAAK, TRESK, TASK-1, or hERG channels). It was designed by studying spadin's blood degradation products to identify the minimal active fragment.

Has PE-22-28 been tested in humans?

No. As of March 2026, neither PE-22-28 nor spadin has been tested in any published human clinical trial. All efficacy and safety data come from cell-based assays (patch-clamp electrophysiology, cortical neuron cultures) and mouse behavioral studies. No studies are registered on ClinicalTrials.gov. The research group has stated their goal is to complete preclinical development before launching human trials, but no timeline has been provided.

How does PE-22-28 produce antidepressant effects?

PE-22-28 blocks the TREK-1 two-pore potassium channel, which normally stabilizes neuronal resting membrane potential and dampens excitability. By inhibiting TREK-1, PE-22-28 depolarizes neurons, enhancing serotonergic neurotransmission (similar to what occurs in TREK-1 knockout mice, which are depression-resistant). Downstream, this activates MAPK and PI3K pathways, upregulates BDNF, increases CREB phosphorylation, promotes hippocampal neurogenesis, and enhances synaptogenesis. Unlike SSRIs, which take 3-4 weeks, PE-22-28 produces antidepressant effects in mice within 4 days.

Is PE-22-28 being studied for hair loss?

No. PE-22-28 is not being studied for hair loss or hair growth in any published research. This appears to be a misconception. PE-22-28 is being researched exclusively for mood disorders (depression), cognitive enhancement, and neuroprotection. Peptides that have been studied for hair growth include copper peptides (GHK-Cu) and thymosin beta-4, but PE-22-28 is not among them.

Is PE-22-28 a phosphodiesterase inhibitor?

No. PE-22-28 is a TREK-1 potassium channel inhibitor, not a phosphodiesterase (PDE) inhibitor. This is a common mischaracterization. While both TREK-1 inhibitors and PDE inhibitors can enhance cognitive function through different mechanisms, PE-22-28 works specifically by blocking the TREK-1 two-pore domain potassium channel. Phosphodiesterase inhibitors (like rolipram, cilostazol) work by preventing breakdown of cyclic nucleotides (cAMP, cGMP).

Is PE-22-28 safe to use?

There is no established human safety profile for PE-22-28. In preclinical studies, PE-22-28 and the parent compound spadin showed no cardiac toxicity (no hERG channel effects, no blood pressure or pulse changes), no interference with pain, epilepsy, or ischemia pathways, and high selectivity for TREK-1 over other potassium channels. However, the absence of any human data means safety in humans is entirely unknown. Anyone using PE-22-28 is doing so with an unapproved research compound at their own risk.